Therapeutic compounds comprised of anti-FC receptor binding agents
US6365161B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 30, 1999 |
| Grant date | Apr 2, 2002 |
| Priority date | — |
| Expiry date | Jul 30, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Multispecific molecules which target immune cells are disclosed. The molecules are “multispecific” because they bind to multiple (two or more), distinct targets, one of which is a molecule on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to a molecule on an effector cell, such as an Fc receptor, and at least one portion (e.g., two, three, four or more portions) which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen “multimer complexes” comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC. Therefore, these molecules can be used to induce or enhance an immune response either in vivo or in vitro against a normally non-immunogenic protein, such as a self-antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.